Lauren O Bakaletz

Contact Information

Call us at: (614)722-2915

Fax us at: (614)722-2818

Email Lauren O. Bakaletz, PhD

Center for Microbial PathogenesisAbigail Wexner Research Institute700 Childrens DriveColumbus, OH 43205 (map)

Learn more about Lauren O. Bakaletz

Biography

Lauren O. Bakaletz, PhD, is a principal investigator in, and the director of, the Center for Microbial Pathogenesis at the Abigail Wexner Research Institute at Nationwide Children’s Hospital and the Tillie E. Coleman Endowed Chair in Pediatric Research. She is a Professor in the Departments of Pediatrics and of Otolaryngology at The Ohio State University College of Medicine.

Academic and Clinical Areas

Center for Microbial Pathogenesis

Director

The Research Institute

Vice President

Infectious Diseases Fellowship

Faculty

Primary Department

Center for Microbial Pathogenesis

Awards, Honors & Organizations

Allen Distinguished Scholar in Pediatric Research, Abigail Wexner Research Institute at Nationwide Children’s Hospital, 2021 Tillie E. Coleman Endowed Chair in Pediatric Research, Nationwide Children’s Hospital, 2006 Fellow, American Association for the Advancement of Science, 2021 - Present Chair, Topics in Bacteriology, Special Emphasis Panel, ZRG1 IDIA-W (80), National Institutes of Health, 2021 - 2021 Chair, Topics in Bacterial Pathogenesis, Special Emphasis Panel, ZRG1 IDIA-B (80), National Institutes of Health, 2021 - 2021 Fellow, American Academy of Microbiology, 2020 - Present Chair, Host Interactions with Bacterial Pathogens (HIBP) Study Section, National Institutes of Health, 2017 - 2019 College of Medicine Distinguished Professor, The Ohio State University, 2013 - Present The Ohio State University, College of Medicine Distinguished Professor, 2013 - Present Director, Executive Committee, International Society for Otitis Media (ISOM), 2012 - Present Director, Executive Committee, International Society for Otitis Media (ISOM), 2012 - Present National Deafness and Other Communication Disorders Advisory Council, National Institutes of Health, 2010 - 2014 National Deafness and Other Communication Disorders Advisory Council, National Institutes of Health, 2010 - 2014 Editorial Board, Infection and Immunity, 2008 - 2016 Editorial Board, Infection and Immunity, 2008 - 2016 Tillie E. Coleman Endowed Chair in Pediatric Research, Nationwide Children’s Hospital, 2006 - Present

Research

Lab(s)

Center for Microbial Pathogenesis

The research program of the Bakaletz Lab is focused on determining the molecular mechanisms that underlie polymicrobial infections of the respiratory tract, including otitis media (or middle ear infections, a highly prevalent pediatric disease worldwide), cystic fibrosis, chronic rhinosinusitis and COPD, among others. Her laboratory also studies bacterial biofilms in an effort to develop novel strategies for effective eradication of the associated highly recalcitrant diseases. Publications

                  Jurcisek JA, Hofer LK, Goodman SD, Bakaletz LO. Monoclonal antibodies that target extracellular DNABII proteins or the type IV pilus of nontypeable Haemophilus influenzae (NTHI) worked additively to disrupt 2-genera biofilms. Biofilm. 2022 Dec; 4: 100096.

                


                  Garai P, Atack JM, Wills BM, Jennings MP, Bakaletz LO, Brockman KL. Adherence of Nontypeable Haemophilus influenzae to Cells and Substrates of the Airway Is Differentially Regulated by Individual ModA Phasevarions. Microbiol Spectr. 2022 Dec 13;  e0409322.

                


                  Almeida C, Bakaletz LO. Editorial: Women in biofilms 2021. Front Cell Infect Microbiol. 2022; 12: 1035280.

                


                  Buzzo JR, Devaraj A, Gloag ES, Jurcisek JA, Robledo-Avila F, Kesler T, Wilbanks K, Mashburn-Warren L, Balu S, Wickham J, Novotny LA, Stoodley P, Bakaletz LO, Goodman SD. Z-form extracellular DNA is a structural component of the bacterial biofilm matrix. Cell. 2021 Nov 11; 184: 5740-5758.e17.

                


                  Mokrzan EM, Ahearn CP, Buzzo JR, Novotny LA, Zhang Y, Goodman SD, Bakaletz LO. Nontypeable Haemophilus influenzae newly released (NRel) from biofilms by antibody-mediated dispersal versus antibody-mediated disruption are phenotypically distinct. Biofilm. 2020 Dec; 2: 100039.

                


                  Novotny LA, Goodman SD, Bakaletz LO. Targeting a bacterial DNABII protein with a chimeric peptide immunogen or humanised monoclonal antibody to prevent or treat recalcitrant biofilm-mediated infections. EBioMedicine. 2020 Sep; 59: 102867.

                


                  Martyn L, Sethia R, Chon R, Novotny L, Goodman SD, Elmaraghy C, Bakaletz LO. Antibodies against the DNABII protein integration host factor (IHF) inhibit sinus implant biofilms. Laryngoscope. 2020 Jun; 130: 1364-1371.

                


                  Barron CL, Kamel-Abusalha LB, Sethia R, Goodman SD, Elmaraghy CA, Bakaletz LO. Identification of essential biofilm proteins in middle ear fluids of otitis media with effusion patients. Laryngoscope. 2020 Mar; 130: 806-811.

                


                  Novotny LA, Bakaletz LO. Transcutaneous immunization with a nontypeable Haemophilus influenzae dual adhesin-directed immunogen induces durable and boostable immunity. Vaccine. 2020 Feb 28; 38: 2378-2386.

                


                  Ysebaert C, Denoël P, Weynants V, Bakaletz LO, Novotny LA, Godfroid F, Hermand P. A Protein E-PilA fusion protein shows vaccine potential against nontypeable Haemophilus influenzae in mice and chinchillas. Infect Immun. 2019 May 20;  

                


                  Novotny LA, Brockman KL, Mokrzan EM, Jurcisek JA, Bakaletz LO. Biofilm biology and vaccine strategies for otitis media due to nontypeable Haemophilus influenzae. J Pediatr Infect Dis. 2019 Feb; 14: 69-77.

                


                  Atack JM, Bakaletz LO, Jennings MP. High-Depth RNA-Seq Data Sets for Studying Gene Expression Changes Mediated by Phase-Variable DNA Methyltransferases in Nontypeable Haemophilus influenzae. Microbiol Resour Announc. 2019 Jan; 8: 

                


                  Novotny LA, Goodman SD, Bakaletz LO. Redirecting the immune response towards immunoprotective domains of a DNABII protein resolves experimental otitis media. NPJ Vaccines. 2019; 4: 43.

                


                  Dagan R, Pelton S, Bakaletz L, Cohen R. First Otitis Media and Pneumococcal Conjugate Vaccine Serotypes in Infants. Pediatr Infect Dis J. 2018 Dec; 37: e351-e352.

                


                  Blakeway LV, Tan A, Lappan R, Ariff A, Pickering JL, Peacock CS, Blyth CC, Kahler CM, Chang BJ, Lehmann D, Kirkham LS, Murphy TF, Jennings MP, Bakaletz LO, Atack JM, Peak IRA, Seib KL. Moraxella catarrhalis Restriction-Modification Systems are Associated with Phylogenetic Lineage and Disease. Genome Biol Evol. 2018 Oct 18;  

                


                  Bakaletz LO, Novotny LA. Nontypeable Haemophilus influenzae (NTHi). Trends Microbiol. 2018 Aug; 26: 727-728.

                


                  Atack JM, Tan A, Bakaletz LO, Jennings MP, Seib KL. Phasevarions of Bacterial Pathogens: Methylomics Sheds New Light on Old Enemies. Trends Microbiol. 2018 Aug; 26: 715-726.

                


                  Atack JM, Murphy TF, Bakaletz LO, Seib KL, Jennings MP. Closed Complete Genome Sequences of Two Nontypeable Haemophilus influenzae Strains Containing Novel modA Alleles from the Sputum of Patients with Chronic Obstructive Pulmonary Disease. Microbiol Resour Announc. 2018 Jul; 7: 

View More Publications

Professional Experience

2020 - Present Scientific Advisory Board, Clarametyx Biosciences, Scientific Founder and Member2017 - Present Scioto Biosciences, Scientific Founder2017 - Present Internal Advisory Board, Cure Cystic Fibrosis Columbus (C3), Member2012 - Present Board of Directors, International Society for Otitis Media (ISOM), Member2008 - Present The Research Institute at Nationwide Children’s Hospital, The Ohio State University, Professor, Dept. of Otolaryngology2008 - Present The Ohio State University, Professor, Dept. of Otolaryngology2007 - Present The Research Institute at Nationwide Children’s Hospital, The Ohio State University, Professor, Dept. of Pediatrics2007 - Present The Research Institute at Nationwide Children’s Hospital, Vice President for Basic Science Research2006 - Present Abigail Wexner Research Institute at Nationwide Children’s Hospital, Vice President, Basic Sciences Research2003 - Present Abigail Wexner Research Institute at Nationwide Children’s Hospital, Director, Center for Microbial Pathogenesis2000 - Present Abigail Wexner Research Institute at Nationwide Children’s Hospital, The Ohio State University, Professor, Dept. of Pediatrics2000 - Present Abigail Wexner Research Institute at Nationwide Children’s Hospital, The Ohio State University, Professor, Dept. of Pediatrics2021 - 2023 Ohio Third Frontier Commission, Member2015 - 2019 National Institutes of Health, Host Interactions with Bacterial Pathogens (HIBP) Study Section, Member2006 - 2007 Vice President for Basic Science Research, Columbus Children’s Research Institute2000 - 2007 Children’s Research Institute, The Ohio State University, Professor, Dept. of Pediatrics1998 - 2000 Children’s Research Institute, The Ohio State University, Associate Professor, Dept. of Pediatrics1998 - 2000 2000 Children’s Research Institute, The Ohio State University, Associate Professor, Dept. of Pediatrics1993 - 1998 The Ohio State University, Associate Professor, Dept. of Otolaryngology1993 - 1998 The Ohio State University, Associate Professor, Dept. of Otolaryngology1985 - 1986 The Ohio State University, Post-doctoral Researcher, Dept. of Otolaryngology1985 - 1986 The Ohio State University, Post-doctoral Researcher, Dept. of Otolaryngology

Contact Information

Center for Microbial Pathogenesis

Call us at: (614)722-2915

Fax us at: (614)722-2818

Email Lauren O Bakaletz

                    Abigail Wexner Research Institute700 Childrens DriveColumbus, OH 43205 (map)

Contact Information

Call us at: (614)722-2915

Fax us at: (614)722-2818

Email Lauren O. Bakaletz, PhD

Center for Microbial PathogenesisAbigail Wexner Research Institute700 Childrens DriveColumbus, OH 43205 (map)

Learn more about Lauren O. Bakaletz

Biography

Lauren O. Bakaletz, PhD, is a principal investigator in, and the director of, the Center for Microbial Pathogenesis at the Abigail Wexner Research Institute at Nationwide Children’s Hospital and the Tillie E. Coleman Endowed Chair in Pediatric Research. She is a Professor in the Departments of Pediatrics and of Otolaryngology at The Ohio State University College of Medicine.

Academic and Clinical Areas

Center for Microbial Pathogenesis

Director

The Research Institute

Vice President

Infectious Diseases Fellowship

Faculty

Primary Department

Center for Microbial Pathogenesis

Awards, Honors & Organizations

Allen Distinguished Scholar in Pediatric Research, Abigail Wexner Research Institute at Nationwide Children’s Hospital, 2021 Tillie E. Coleman Endowed Chair in Pediatric Research, Nationwide Children’s Hospital, 2006 Fellow, American Association for the Advancement of Science, 2021 - Present Chair, Topics in Bacteriology, Special Emphasis Panel, ZRG1 IDIA-W (80), National Institutes of Health, 2021 - 2021 Chair, Topics in Bacterial Pathogenesis, Special Emphasis Panel, ZRG1 IDIA-B (80), National Institutes of Health, 2021 - 2021 Fellow, American Academy of Microbiology, 2020 - Present Chair, Host Interactions with Bacterial Pathogens (HIBP) Study Section, National Institutes of Health, 2017 - 2019 College of Medicine Distinguished Professor, The Ohio State University, 2013 - Present The Ohio State University, College of Medicine Distinguished Professor, 2013 - Present Director, Executive Committee, International Society for Otitis Media (ISOM), 2012 - Present Director, Executive Committee, International Society for Otitis Media (ISOM), 2012 - Present National Deafness and Other Communication Disorders Advisory Council, National Institutes of Health, 2010 - 2014 National Deafness and Other Communication Disorders Advisory Council, National Institutes of Health, 2010 - 2014 Editorial Board, Infection and Immunity, 2008 - 2016 Editorial Board, Infection and Immunity, 2008 - 2016 Tillie E. Coleman Endowed Chair in Pediatric Research, Nationwide Children’s Hospital, 2006 - Present

Research

Lab(s)

Center for Microbial Pathogenesis

The research program of the Bakaletz Lab is focused on determining the molecular mechanisms that underlie polymicrobial infections of the respiratory tract, including otitis media (or middle ear infections, a highly prevalent pediatric disease worldwide), cystic fibrosis, chronic rhinosinusitis and COPD, among others. Her laboratory also studies bacterial biofilms in an effort to develop novel strategies for effective eradication of the associated highly recalcitrant diseases. Publications

                  Jurcisek JA, Hofer LK, Goodman SD, Bakaletz LO. Monoclonal antibodies that target extracellular DNABII proteins or the type IV pilus of nontypeable Haemophilus influenzae (NTHI) worked additively to disrupt 2-genera biofilms. Biofilm. 2022 Dec; 4: 100096.

                


                  Garai P, Atack JM, Wills BM, Jennings MP, Bakaletz LO, Brockman KL. Adherence of Nontypeable Haemophilus influenzae to Cells and Substrates of the Airway Is Differentially Regulated by Individual ModA Phasevarions. Microbiol Spectr. 2022 Dec 13;  e0409322.

                


                  Almeida C, Bakaletz LO. Editorial: Women in biofilms 2021. Front Cell Infect Microbiol. 2022; 12: 1035280.

                


                  Buzzo JR, Devaraj A, Gloag ES, Jurcisek JA, Robledo-Avila F, Kesler T, Wilbanks K, Mashburn-Warren L, Balu S, Wickham J, Novotny LA, Stoodley P, Bakaletz LO, Goodman SD. Z-form extracellular DNA is a structural component of the bacterial biofilm matrix. Cell. 2021 Nov 11; 184: 5740-5758.e17.

                


                  Mokrzan EM, Ahearn CP, Buzzo JR, Novotny LA, Zhang Y, Goodman SD, Bakaletz LO. Nontypeable Haemophilus influenzae newly released (NRel) from biofilms by antibody-mediated dispersal versus antibody-mediated disruption are phenotypically distinct. Biofilm. 2020 Dec; 2: 100039.

                


                  Novotny LA, Goodman SD, Bakaletz LO. Targeting a bacterial DNABII protein with a chimeric peptide immunogen or humanised monoclonal antibody to prevent or treat recalcitrant biofilm-mediated infections. EBioMedicine. 2020 Sep; 59: 102867.

                


                  Martyn L, Sethia R, Chon R, Novotny L, Goodman SD, Elmaraghy C, Bakaletz LO. Antibodies against the DNABII protein integration host factor (IHF) inhibit sinus implant biofilms. Laryngoscope. 2020 Jun; 130: 1364-1371.

                


                  Barron CL, Kamel-Abusalha LB, Sethia R, Goodman SD, Elmaraghy CA, Bakaletz LO. Identification of essential biofilm proteins in middle ear fluids of otitis media with effusion patients. Laryngoscope. 2020 Mar; 130: 806-811.

                


                  Novotny LA, Bakaletz LO. Transcutaneous immunization with a nontypeable Haemophilus influenzae dual adhesin-directed immunogen induces durable and boostable immunity. Vaccine. 2020 Feb 28; 38: 2378-2386.

                


                  Ysebaert C, Denoël P, Weynants V, Bakaletz LO, Novotny LA, Godfroid F, Hermand P. A Protein E-PilA fusion protein shows vaccine potential against nontypeable Haemophilus influenzae in mice and chinchillas. Infect Immun. 2019 May 20;  

                


                  Novotny LA, Brockman KL, Mokrzan EM, Jurcisek JA, Bakaletz LO. Biofilm biology and vaccine strategies for otitis media due to nontypeable Haemophilus influenzae. J Pediatr Infect Dis. 2019 Feb; 14: 69-77.

                


                  Atack JM, Bakaletz LO, Jennings MP. High-Depth RNA-Seq Data Sets for Studying Gene Expression Changes Mediated by Phase-Variable DNA Methyltransferases in Nontypeable Haemophilus influenzae. Microbiol Resour Announc. 2019 Jan; 8: 

                


                  Novotny LA, Goodman SD, Bakaletz LO. Redirecting the immune response towards immunoprotective domains of a DNABII protein resolves experimental otitis media. NPJ Vaccines. 2019; 4: 43.

                


                  Dagan R, Pelton S, Bakaletz L, Cohen R. First Otitis Media and Pneumococcal Conjugate Vaccine Serotypes in Infants. Pediatr Infect Dis J. 2018 Dec; 37: e351-e352.

                


                  Blakeway LV, Tan A, Lappan R, Ariff A, Pickering JL, Peacock CS, Blyth CC, Kahler CM, Chang BJ, Lehmann D, Kirkham LS, Murphy TF, Jennings MP, Bakaletz LO, Atack JM, Peak IRA, Seib KL. Moraxella catarrhalis Restriction-Modification Systems are Associated with Phylogenetic Lineage and Disease. Genome Biol Evol. 2018 Oct 18;  

                


                  Bakaletz LO, Novotny LA. Nontypeable Haemophilus influenzae (NTHi). Trends Microbiol. 2018 Aug; 26: 727-728.

                


                  Atack JM, Tan A, Bakaletz LO, Jennings MP, Seib KL. Phasevarions of Bacterial Pathogens: Methylomics Sheds New Light on Old Enemies. Trends Microbiol. 2018 Aug; 26: 715-726.

                


                  Atack JM, Murphy TF, Bakaletz LO, Seib KL, Jennings MP. Closed Complete Genome Sequences of Two Nontypeable Haemophilus influenzae Strains Containing Novel modA Alleles from the Sputum of Patients with Chronic Obstructive Pulmonary Disease. Microbiol Resour Announc. 2018 Jul; 7: 

View More Publications

Professional Experience

2020 - Present Scientific Advisory Board, Clarametyx Biosciences, Scientific Founder and Member2017 - Present Scioto Biosciences, Scientific Founder2017 - Present Internal Advisory Board, Cure Cystic Fibrosis Columbus (C3), Member2012 - Present Board of Directors, International Society for Otitis Media (ISOM), Member2008 - Present The Research Institute at Nationwide Children’s Hospital, The Ohio State University, Professor, Dept. of Otolaryngology2008 - Present The Ohio State University, Professor, Dept. of Otolaryngology2007 - Present The Research Institute at Nationwide Children’s Hospital, The Ohio State University, Professor, Dept. of Pediatrics2007 - Present The Research Institute at Nationwide Children’s Hospital, Vice President for Basic Science Research2006 - Present Abigail Wexner Research Institute at Nationwide Children’s Hospital, Vice President, Basic Sciences Research2003 - Present Abigail Wexner Research Institute at Nationwide Children’s Hospital, Director, Center for Microbial Pathogenesis2000 - Present Abigail Wexner Research Institute at Nationwide Children’s Hospital, The Ohio State University, Professor, Dept. of Pediatrics2000 - Present Abigail Wexner Research Institute at Nationwide Children’s Hospital, The Ohio State University, Professor, Dept. of Pediatrics2021 - 2023 Ohio Third Frontier Commission, Member2015 - 2019 National Institutes of Health, Host Interactions with Bacterial Pathogens (HIBP) Study Section, Member2006 - 2007 Vice President for Basic Science Research, Columbus Children’s Research Institute2000 - 2007 Children’s Research Institute, The Ohio State University, Professor, Dept. of Pediatrics1998 - 2000 Children’s Research Institute, The Ohio State University, Associate Professor, Dept. of Pediatrics1998 - 2000 2000 Children’s Research Institute, The Ohio State University, Associate Professor, Dept. of Pediatrics1993 - 1998 The Ohio State University, Associate Professor, Dept. of Otolaryngology1993 - 1998 The Ohio State University, Associate Professor, Dept. of Otolaryngology1985 - 1986 The Ohio State University, Post-doctoral Researcher, Dept. of Otolaryngology1985 - 1986 The Ohio State University, Post-doctoral Researcher, Dept. of Otolaryngology

Contact Information

Center for Microbial Pathogenesis

Call us at: (614)722-2915

Fax us at: (614)722-2818

Email Lauren O Bakaletz

                    Abigail Wexner Research Institute700 Childrens DriveColumbus, OH 43205 (map)

Contact Information

Call us at: (614)722-2915

Fax us at: (614)722-2818

Email Lauren O. Bakaletz, PhD

Center for Microbial PathogenesisAbigail Wexner Research Institute700 Childrens DriveColumbus, OH 43205 (map)

Learn more about Lauren O. Bakaletz

Contact Information

• Call us at:
• (614)722-2915
• Fax us at:
• (614)722-2818
• Email Lauren O. Bakaletz, PhD
• Center for Microbial PathogenesisAbigail Wexner Research Institute700 Childrens DriveColumbus, OH 43205 (map)

Learn more about Lauren O. Bakaletz

Biography

Lauren O. Bakaletz, PhD, is a principal investigator in, and the director of, the Center for Microbial Pathogenesis at the Abigail Wexner Research Institute at Nationwide Children’s Hospital and the Tillie E. Coleman Endowed Chair in Pediatric Research. She is a Professor in the Departments of Pediatrics and of Otolaryngology at The Ohio State University College of Medicine.

Biography

Lauren O. Bakaletz, PhD, is a principal investigator in, and the director of, the Center for Microbial Pathogenesis at the Abigail Wexner Research Institute at Nationwide Children’s Hospital and the Tillie E. Coleman Endowed Chair in Pediatric Research. She is a Professor in the Departments of Pediatrics and of Otolaryngology at The Ohio State University College of Medicine.

Biography

Lauren O. Bakaletz, PhD, is a principal investigator in, and the director of, the Center for Microbial Pathogenesis at the Abigail Wexner Research Institute at Nationwide Children’s Hospital and the Tillie E. Coleman Endowed Chair in Pediatric Research. She is a Professor in the Departments of Pediatrics and of Otolaryngology at The Ohio State University College of Medicine.

Lauren O. Bakaletz, PhD, is a principal investigator in, and the director of, the Center for Microbial Pathogenesis at the Abigail Wexner Research Institute at Nationwide Children’s Hospital and the Tillie E. Coleman Endowed Chair in Pediatric Research. She is a Professor in the Departments of Pediatrics and of Otolaryngology at The Ohio State University College of Medicine.

Lauren O. Bakaletz, PhD, is a principal investigator in, and the director of, the Center for Microbial Pathogenesis at the Abigail Wexner Research Institute at Nationwide Children’s Hospital and the Tillie E. Coleman Endowed Chair in Pediatric Research. She is a Professor in the Departments of Pediatrics and of Otolaryngology at The Ohio State University College of Medicine.

Academic and Clinical Areas

Center for Microbial Pathogenesis

Director

The Research Institute

Vice President

Infectious Diseases Fellowship

Faculty

Primary Department

Center for Microbial Pathogenesis

Academic and Clinical Areas

Center for Microbial Pathogenesis

Director

The Research Institute

Vice President

Infectious Diseases Fellowship

Faculty

Primary Department

Center for Microbial Pathogenesis

Academic and Clinical Areas

Center for Microbial Pathogenesis

Director

The Research Institute

Vice President

Infectious Diseases Fellowship

Faculty

Primary Department

Center for Microbial Pathogenesis

Center for Microbial Pathogenesis

Director

The Research Institute

Vice President

Infectious Diseases Fellowship

Faculty

Primary Department

Center for Microbial Pathogenesis

• Center for Microbial Pathogenesis
• Director
• The Research Institute
• Vice President
• Infectious Diseases Fellowship
• Faculty
• Primary Department
• Center for Microbial Pathogenesis

Awards, Honors & Organizations

Allen Distinguished Scholar in Pediatric Research, Abigail Wexner Research Institute at Nationwide Children’s Hospital, 2021 Tillie E. Coleman Endowed Chair in Pediatric Research, Nationwide Children’s Hospital, 2006 Fellow, American Association for the Advancement of Science, 2021 - Present Chair, Topics in Bacteriology, Special Emphasis Panel, ZRG1 IDIA-W (80), National Institutes of Health, 2021 - 2021 Chair, Topics in Bacterial Pathogenesis, Special Emphasis Panel, ZRG1 IDIA-B (80), National Institutes of Health, 2021 - 2021 Fellow, American Academy of Microbiology, 2020 - Present Chair, Host Interactions with Bacterial Pathogens (HIBP) Study Section, National Institutes of Health, 2017 - 2019 College of Medicine Distinguished Professor, The Ohio State University, 2013 - Present The Ohio State University, College of Medicine Distinguished Professor, 2013 - Present Director, Executive Committee, International Society for Otitis Media (ISOM), 2012 - Present Director, Executive Committee, International Society for Otitis Media (ISOM), 2012 - Present National Deafness and Other Communication Disorders Advisory Council, National Institutes of Health, 2010 - 2014 National Deafness and Other Communication Disorders Advisory Council, National Institutes of Health, 2010 - 2014 Editorial Board, Infection and Immunity, 2008 - 2016 Editorial Board, Infection and Immunity, 2008 - 2016 Tillie E. Coleman Endowed Chair in Pediatric Research, Nationwide Children’s Hospital, 2006 - Present

Awards, Honors & Organizations

Allen Distinguished Scholar in Pediatric Research, Abigail Wexner Research Institute at Nationwide Children’s Hospital, 2021 Tillie E. Coleman Endowed Chair in Pediatric Research, Nationwide Children’s Hospital, 2006 Fellow, American Association for the Advancement of Science, 2021 - Present Chair, Topics in Bacteriology, Special Emphasis Panel, ZRG1 IDIA-W (80), National Institutes of Health, 2021 - 2021 Chair, Topics in Bacterial Pathogenesis, Special Emphasis Panel, ZRG1 IDIA-B (80), National Institutes of Health, 2021 - 2021 Fellow, American Academy of Microbiology, 2020 - Present Chair, Host Interactions with Bacterial Pathogens (HIBP) Study Section, National Institutes of Health, 2017 - 2019 College of Medicine Distinguished Professor, The Ohio State University, 2013 - Present The Ohio State University, College of Medicine Distinguished Professor, 2013 - Present Director, Executive Committee, International Society for Otitis Media (ISOM), 2012 - Present Director, Executive Committee, International Society for Otitis Media (ISOM), 2012 - Present National Deafness and Other Communication Disorders Advisory Council, National Institutes of Health, 2010 - 2014 National Deafness and Other Communication Disorders Advisory Council, National Institutes of Health, 2010 - 2014 Editorial Board, Infection and Immunity, 2008 - 2016 Editorial Board, Infection and Immunity, 2008 - 2016 Tillie E. Coleman Endowed Chair in Pediatric Research, Nationwide Children’s Hospital, 2006 - Present

Awards, Honors & Organizations

Allen Distinguished Scholar in Pediatric Research, Abigail Wexner Research Institute at Nationwide Children’s Hospital, 2021 Tillie E. Coleman Endowed Chair in Pediatric Research, Nationwide Children’s Hospital, 2006 Fellow, American Association for the Advancement of Science, 2021 - Present Chair, Topics in Bacteriology, Special Emphasis Panel, ZRG1 IDIA-W (80), National Institutes of Health, 2021 - 2021 Chair, Topics in Bacterial Pathogenesis, Special Emphasis Panel, ZRG1 IDIA-B (80), National Institutes of Health, 2021 - 2021 Fellow, American Academy of Microbiology, 2020 - Present Chair, Host Interactions with Bacterial Pathogens (HIBP) Study Section, National Institutes of Health, 2017 - 2019 College of Medicine Distinguished Professor, The Ohio State University, 2013 - Present The Ohio State University, College of Medicine Distinguished Professor, 2013 - Present Director, Executive Committee, International Society for Otitis Media (ISOM), 2012 - Present Director, Executive Committee, International Society for Otitis Media (ISOM), 2012 - Present National Deafness and Other Communication Disorders Advisory Council, National Institutes of Health, 2010 - 2014 National Deafness and Other Communication Disorders Advisory Council, National Institutes of Health, 2010 - 2014 Editorial Board, Infection and Immunity, 2008 - 2016 Editorial Board, Infection and Immunity, 2008 - 2016 Tillie E. Coleman Endowed Chair in Pediatric Research, Nationwide Children’s Hospital, 2006 - Present

Allen Distinguished Scholar in Pediatric Research, Abigail Wexner Research Institute at Nationwide Children’s Hospital, 2021 Tillie E. Coleman Endowed Chair in Pediatric Research, Nationwide Children’s Hospital, 2006 Fellow, American Association for the Advancement of Science, 2021 - Present Chair, Topics in Bacteriology, Special Emphasis Panel, ZRG1 IDIA-W (80), National Institutes of Health, 2021 - 2021 Chair, Topics in Bacterial Pathogenesis, Special Emphasis Panel, ZRG1 IDIA-B (80), National Institutes of Health, 2021 - 2021 Fellow, American Academy of Microbiology, 2020 - Present Chair, Host Interactions with Bacterial Pathogens (HIBP) Study Section, National Institutes of Health, 2017 - 2019 College of Medicine Distinguished Professor, The Ohio State University, 2013 - Present The Ohio State University, College of Medicine Distinguished Professor, 2013 - Present Director, Executive Committee, International Society for Otitis Media (ISOM), 2012 - Present Director, Executive Committee, International Society for Otitis Media (ISOM), 2012 - Present National Deafness and Other Communication Disorders Advisory Council, National Institutes of Health, 2010 - 2014 National Deafness and Other Communication Disorders Advisory Council, National Institutes of Health, 2010 - 2014 Editorial Board, Infection and Immunity, 2008 - 2016 Editorial Board, Infection and Immunity, 2008 - 2016 Tillie E. Coleman Endowed Chair in Pediatric Research, Nationwide Children’s Hospital, 2006 - Present

• Allen Distinguished Scholar in Pediatric Research, Abigail Wexner Research Institute at Nationwide Children’s Hospital, 2021
• Tillie E. Coleman Endowed Chair in Pediatric Research, Nationwide Children’s Hospital, 2006
• Fellow, American Association for the Advancement of Science, 2021 - Present
• Chair, Topics in Bacteriology, Special Emphasis Panel, ZRG1 IDIA-W (80), National Institutes of Health, 2021 - 2021
• Chair, Topics in Bacterial Pathogenesis, Special Emphasis Panel, ZRG1 IDIA-B (80), National Institutes of Health, 2021 - 2021
• Fellow, American Academy of Microbiology, 2020 - Present
• Chair, Host Interactions with Bacterial Pathogens (HIBP) Study Section, National Institutes of Health, 2017 - 2019
• College of Medicine Distinguished Professor, The Ohio State University, 2013 - Present
• The Ohio State University, College of Medicine Distinguished Professor, 2013 - Present
• Director, Executive Committee, International Society for Otitis Media (ISOM), 2012 - Present
• Director, Executive Committee, International Society for Otitis Media (ISOM), 2012 - Present
• National Deafness and Other Communication Disorders Advisory Council, National Institutes of Health, 2010 - 2014
• National Deafness and Other Communication Disorders Advisory Council, National Institutes of Health, 2010 - 2014
• Editorial Board, Infection and Immunity, 2008 - 2016
• Editorial Board, Infection and Immunity, 2008 - 2016
• Tillie E. Coleman Endowed Chair in Pediatric Research, Nationwide Children’s Hospital, 2006 - Present

Research

Lab(s)

Center for Microbial Pathogenesis

The research program of the Bakaletz Lab is focused on determining the molecular mechanisms that underlie polymicrobial infections of the respiratory tract, including otitis media (or middle ear infections, a highly prevalent pediatric disease worldwide), cystic fibrosis, chronic rhinosinusitis and COPD, among others. Her laboratory also studies bacterial biofilms in an effort to develop novel strategies for effective eradication of the associated highly recalcitrant diseases. Publications

                  Jurcisek JA, Hofer LK, Goodman SD, Bakaletz LO. Monoclonal antibodies that target extracellular DNABII proteins or the type IV pilus of nontypeable Haemophilus influenzae (NTHI) worked additively to disrupt 2-genera biofilms. Biofilm. 2022 Dec; 4: 100096.

                


                  Garai P, Atack JM, Wills BM, Jennings MP, Bakaletz LO, Brockman KL. Adherence of Nontypeable Haemophilus influenzae to Cells and Substrates of the Airway Is Differentially Regulated by Individual ModA Phasevarions. Microbiol Spectr. 2022 Dec 13;  e0409322.

                


                  Almeida C, Bakaletz LO. Editorial: Women in biofilms 2021. Front Cell Infect Microbiol. 2022; 12: 1035280.

                


                  Buzzo JR, Devaraj A, Gloag ES, Jurcisek JA, Robledo-Avila F, Kesler T, Wilbanks K, Mashburn-Warren L, Balu S, Wickham J, Novotny LA, Stoodley P, Bakaletz LO, Goodman SD. Z-form extracellular DNA is a structural component of the bacterial biofilm matrix. Cell. 2021 Nov 11; 184: 5740-5758.e17.

                


                  Mokrzan EM, Ahearn CP, Buzzo JR, Novotny LA, Zhang Y, Goodman SD, Bakaletz LO. Nontypeable Haemophilus influenzae newly released (NRel) from biofilms by antibody-mediated dispersal versus antibody-mediated disruption are phenotypically distinct. Biofilm. 2020 Dec; 2: 100039.

                


                  Novotny LA, Goodman SD, Bakaletz LO. Targeting a bacterial DNABII protein with a chimeric peptide immunogen or humanised monoclonal antibody to prevent or treat recalcitrant biofilm-mediated infections. EBioMedicine. 2020 Sep; 59: 102867.

                


                  Martyn L, Sethia R, Chon R, Novotny L, Goodman SD, Elmaraghy C, Bakaletz LO. Antibodies against the DNABII protein integration host factor (IHF) inhibit sinus implant biofilms. Laryngoscope. 2020 Jun; 130: 1364-1371.

                


                  Barron CL, Kamel-Abusalha LB, Sethia R, Goodman SD, Elmaraghy CA, Bakaletz LO. Identification of essential biofilm proteins in middle ear fluids of otitis media with effusion patients. Laryngoscope. 2020 Mar; 130: 806-811.

                


                  Novotny LA, Bakaletz LO. Transcutaneous immunization with a nontypeable Haemophilus influenzae dual adhesin-directed immunogen induces durable and boostable immunity. Vaccine. 2020 Feb 28; 38: 2378-2386.

                


                  Ysebaert C, Denoël P, Weynants V, Bakaletz LO, Novotny LA, Godfroid F, Hermand P. A Protein E-PilA fusion protein shows vaccine potential against nontypeable Haemophilus influenzae in mice and chinchillas. Infect Immun. 2019 May 20;  

                


                  Novotny LA, Brockman KL, Mokrzan EM, Jurcisek JA, Bakaletz LO. Biofilm biology and vaccine strategies for otitis media due to nontypeable Haemophilus influenzae. J Pediatr Infect Dis. 2019 Feb; 14: 69-77.

                


                  Atack JM, Bakaletz LO, Jennings MP. High-Depth RNA-Seq Data Sets for Studying Gene Expression Changes Mediated by Phase-Variable DNA Methyltransferases in Nontypeable Haemophilus influenzae. Microbiol Resour Announc. 2019 Jan; 8: 

                


                  Novotny LA, Goodman SD, Bakaletz LO. Redirecting the immune response towards immunoprotective domains of a DNABII protein resolves experimental otitis media. NPJ Vaccines. 2019; 4: 43.

                


                  Dagan R, Pelton S, Bakaletz L, Cohen R. First Otitis Media and Pneumococcal Conjugate Vaccine Serotypes in Infants. Pediatr Infect Dis J. 2018 Dec; 37: e351-e352.

                


                  Blakeway LV, Tan A, Lappan R, Ariff A, Pickering JL, Peacock CS, Blyth CC, Kahler CM, Chang BJ, Lehmann D, Kirkham LS, Murphy TF, Jennings MP, Bakaletz LO, Atack JM, Peak IRA, Seib KL. Moraxella catarrhalis Restriction-Modification Systems are Associated with Phylogenetic Lineage and Disease. Genome Biol Evol. 2018 Oct 18;  

                


                  Bakaletz LO, Novotny LA. Nontypeable Haemophilus influenzae (NTHi). Trends Microbiol. 2018 Aug; 26: 727-728.

                


                  Atack JM, Tan A, Bakaletz LO, Jennings MP, Seib KL. Phasevarions of Bacterial Pathogens: Methylomics Sheds New Light on Old Enemies. Trends Microbiol. 2018 Aug; 26: 715-726.

                


                  Atack JM, Murphy TF, Bakaletz LO, Seib KL, Jennings MP. Closed Complete Genome Sequences of Two Nontypeable Haemophilus influenzae Strains Containing Novel modA Alleles from the Sputum of Patients with Chronic Obstructive Pulmonary Disease. Microbiol Resour Announc. 2018 Jul; 7: 

View More Publications

Research

Lab(s)

Center for Microbial Pathogenesis

The research program of the Bakaletz Lab is focused on determining the molecular mechanisms that underlie polymicrobial infections of the respiratory tract, including otitis media (or middle ear infections, a highly prevalent pediatric disease worldwide), cystic fibrosis, chronic rhinosinusitis and COPD, among others. Her laboratory also studies bacterial biofilms in an effort to develop novel strategies for effective eradication of the associated highly recalcitrant diseases. Publications

                  Jurcisek JA, Hofer LK, Goodman SD, Bakaletz LO. Monoclonal antibodies that target extracellular DNABII proteins or the type IV pilus of nontypeable Haemophilus influenzae (NTHI) worked additively to disrupt 2-genera biofilms. Biofilm. 2022 Dec; 4: 100096.

                


                  Garai P, Atack JM, Wills BM, Jennings MP, Bakaletz LO, Brockman KL. Adherence of Nontypeable Haemophilus influenzae to Cells and Substrates of the Airway Is Differentially Regulated by Individual ModA Phasevarions. Microbiol Spectr. 2022 Dec 13;  e0409322.

                


                  Almeida C, Bakaletz LO. Editorial: Women in biofilms 2021. Front Cell Infect Microbiol. 2022; 12: 1035280.

                


                  Buzzo JR, Devaraj A, Gloag ES, Jurcisek JA, Robledo-Avila F, Kesler T, Wilbanks K, Mashburn-Warren L, Balu S, Wickham J, Novotny LA, Stoodley P, Bakaletz LO, Goodman SD. Z-form extracellular DNA is a structural component of the bacterial biofilm matrix. Cell. 2021 Nov 11; 184: 5740-5758.e17.

                


                  Mokrzan EM, Ahearn CP, Buzzo JR, Novotny LA, Zhang Y, Goodman SD, Bakaletz LO. Nontypeable Haemophilus influenzae newly released (NRel) from biofilms by antibody-mediated dispersal versus antibody-mediated disruption are phenotypically distinct. Biofilm. 2020 Dec; 2: 100039.

                


                  Novotny LA, Goodman SD, Bakaletz LO. Targeting a bacterial DNABII protein with a chimeric peptide immunogen or humanised monoclonal antibody to prevent or treat recalcitrant biofilm-mediated infections. EBioMedicine. 2020 Sep; 59: 102867.

                


                  Martyn L, Sethia R, Chon R, Novotny L, Goodman SD, Elmaraghy C, Bakaletz LO. Antibodies against the DNABII protein integration host factor (IHF) inhibit sinus implant biofilms. Laryngoscope. 2020 Jun; 130: 1364-1371.

                


                  Barron CL, Kamel-Abusalha LB, Sethia R, Goodman SD, Elmaraghy CA, Bakaletz LO. Identification of essential biofilm proteins in middle ear fluids of otitis media with effusion patients. Laryngoscope. 2020 Mar; 130: 806-811.

                


                  Novotny LA, Bakaletz LO. Transcutaneous immunization with a nontypeable Haemophilus influenzae dual adhesin-directed immunogen induces durable and boostable immunity. Vaccine. 2020 Feb 28; 38: 2378-2386.

                


                  Ysebaert C, Denoël P, Weynants V, Bakaletz LO, Novotny LA, Godfroid F, Hermand P. A Protein E-PilA fusion protein shows vaccine potential against nontypeable Haemophilus influenzae in mice and chinchillas. Infect Immun. 2019 May 20;  

                


                  Novotny LA, Brockman KL, Mokrzan EM, Jurcisek JA, Bakaletz LO. Biofilm biology and vaccine strategies for otitis media due to nontypeable Haemophilus influenzae. J Pediatr Infect Dis. 2019 Feb; 14: 69-77.

                


                  Atack JM, Bakaletz LO, Jennings MP. High-Depth RNA-Seq Data Sets for Studying Gene Expression Changes Mediated by Phase-Variable DNA Methyltransferases in Nontypeable Haemophilus influenzae. Microbiol Resour Announc. 2019 Jan; 8: 

                


                  Novotny LA, Goodman SD, Bakaletz LO. Redirecting the immune response towards immunoprotective domains of a DNABII protein resolves experimental otitis media. NPJ Vaccines. 2019; 4: 43.

                


                  Dagan R, Pelton S, Bakaletz L, Cohen R. First Otitis Media and Pneumococcal Conjugate Vaccine Serotypes in Infants. Pediatr Infect Dis J. 2018 Dec; 37: e351-e352.

                


                  Blakeway LV, Tan A, Lappan R, Ariff A, Pickering JL, Peacock CS, Blyth CC, Kahler CM, Chang BJ, Lehmann D, Kirkham LS, Murphy TF, Jennings MP, Bakaletz LO, Atack JM, Peak IRA, Seib KL. Moraxella catarrhalis Restriction-Modification Systems are Associated with Phylogenetic Lineage and Disease. Genome Biol Evol. 2018 Oct 18;  

                


                  Bakaletz LO, Novotny LA. Nontypeable Haemophilus influenzae (NTHi). Trends Microbiol. 2018 Aug; 26: 727-728.

                


                  Atack JM, Tan A, Bakaletz LO, Jennings MP, Seib KL. Phasevarions of Bacterial Pathogens: Methylomics Sheds New Light on Old Enemies. Trends Microbiol. 2018 Aug; 26: 715-726.

                


                  Atack JM, Murphy TF, Bakaletz LO, Seib KL, Jennings MP. Closed Complete Genome Sequences of Two Nontypeable Haemophilus influenzae Strains Containing Novel modA Alleles from the Sputum of Patients with Chronic Obstructive Pulmonary Disease. Microbiol Resour Announc. 2018 Jul; 7: 

View More Publications

Research

Lab(s)

Center for Microbial Pathogenesis

The research program of the Bakaletz Lab is focused on determining the molecular mechanisms that underlie polymicrobial infections of the respiratory tract, including otitis media (or middle ear infections, a highly prevalent pediatric disease worldwide), cystic fibrosis, chronic rhinosinusitis and COPD, among others. Her laboratory also studies bacterial biofilms in an effort to develop novel strategies for effective eradication of the associated highly recalcitrant diseases. Publications

                  Jurcisek JA, Hofer LK, Goodman SD, Bakaletz LO. Monoclonal antibodies that target extracellular DNABII proteins or the type IV pilus of nontypeable Haemophilus influenzae (NTHI) worked additively to disrupt 2-genera biofilms. Biofilm. 2022 Dec; 4: 100096.

                


                  Garai P, Atack JM, Wills BM, Jennings MP, Bakaletz LO, Brockman KL. Adherence of Nontypeable Haemophilus influenzae to Cells and Substrates of the Airway Is Differentially Regulated by Individual ModA Phasevarions. Microbiol Spectr. 2022 Dec 13;  e0409322.

                


                  Almeida C, Bakaletz LO. Editorial: Women in biofilms 2021. Front Cell Infect Microbiol. 2022; 12: 1035280.

                


                  Buzzo JR, Devaraj A, Gloag ES, Jurcisek JA, Robledo-Avila F, Kesler T, Wilbanks K, Mashburn-Warren L, Balu S, Wickham J, Novotny LA, Stoodley P, Bakaletz LO, Goodman SD. Z-form extracellular DNA is a structural component of the bacterial biofilm matrix. Cell. 2021 Nov 11; 184: 5740-5758.e17.

                


                  Mokrzan EM, Ahearn CP, Buzzo JR, Novotny LA, Zhang Y, Goodman SD, Bakaletz LO. Nontypeable Haemophilus influenzae newly released (NRel) from biofilms by antibody-mediated dispersal versus antibody-mediated disruption are phenotypically distinct. Biofilm. 2020 Dec; 2: 100039.

                


                  Novotny LA, Goodman SD, Bakaletz LO. Targeting a bacterial DNABII protein with a chimeric peptide immunogen or humanised monoclonal antibody to prevent or treat recalcitrant biofilm-mediated infections. EBioMedicine. 2020 Sep; 59: 102867.

                


                  Martyn L, Sethia R, Chon R, Novotny L, Goodman SD, Elmaraghy C, Bakaletz LO. Antibodies against the DNABII protein integration host factor (IHF) inhibit sinus implant biofilms. Laryngoscope. 2020 Jun; 130: 1364-1371.

                


                  Barron CL, Kamel-Abusalha LB, Sethia R, Goodman SD, Elmaraghy CA, Bakaletz LO. Identification of essential biofilm proteins in middle ear fluids of otitis media with effusion patients. Laryngoscope. 2020 Mar; 130: 806-811.

                


                  Novotny LA, Bakaletz LO. Transcutaneous immunization with a nontypeable Haemophilus influenzae dual adhesin-directed immunogen induces durable and boostable immunity. Vaccine. 2020 Feb 28; 38: 2378-2386.

                


                  Ysebaert C, Denoël P, Weynants V, Bakaletz LO, Novotny LA, Godfroid F, Hermand P. A Protein E-PilA fusion protein shows vaccine potential against nontypeable Haemophilus influenzae in mice and chinchillas. Infect Immun. 2019 May 20;  

                


                  Novotny LA, Brockman KL, Mokrzan EM, Jurcisek JA, Bakaletz LO. Biofilm biology and vaccine strategies for otitis media due to nontypeable Haemophilus influenzae. J Pediatr Infect Dis. 2019 Feb; 14: 69-77.

                


                  Atack JM, Bakaletz LO, Jennings MP. High-Depth RNA-Seq Data Sets for Studying Gene Expression Changes Mediated by Phase-Variable DNA Methyltransferases in Nontypeable Haemophilus influenzae. Microbiol Resour Announc. 2019 Jan; 8: 

                


                  Novotny LA, Goodman SD, Bakaletz LO. Redirecting the immune response towards immunoprotective domains of a DNABII protein resolves experimental otitis media. NPJ Vaccines. 2019; 4: 43.

                


                  Dagan R, Pelton S, Bakaletz L, Cohen R. First Otitis Media and Pneumococcal Conjugate Vaccine Serotypes in Infants. Pediatr Infect Dis J. 2018 Dec; 37: e351-e352.

                


                  Blakeway LV, Tan A, Lappan R, Ariff A, Pickering JL, Peacock CS, Blyth CC, Kahler CM, Chang BJ, Lehmann D, Kirkham LS, Murphy TF, Jennings MP, Bakaletz LO, Atack JM, Peak IRA, Seib KL. Moraxella catarrhalis Restriction-Modification Systems are Associated with Phylogenetic Lineage and Disease. Genome Biol Evol. 2018 Oct 18;  

                


                  Bakaletz LO, Novotny LA. Nontypeable Haemophilus influenzae (NTHi). Trends Microbiol. 2018 Aug; 26: 727-728.

                


                  Atack JM, Tan A, Bakaletz LO, Jennings MP, Seib KL. Phasevarions of Bacterial Pathogens: Methylomics Sheds New Light on Old Enemies. Trends Microbiol. 2018 Aug; 26: 715-726.

                


                  Atack JM, Murphy TF, Bakaletz LO, Seib KL, Jennings MP. Closed Complete Genome Sequences of Two Nontypeable Haemophilus influenzae Strains Containing Novel modA Alleles from the Sputum of Patients with Chronic Obstructive Pulmonary Disease. Microbiol Resour Announc. 2018 Jul; 7: 

View More Publications

Lab(s)

Center for Microbial Pathogenesis

The research program of the Bakaletz Lab is focused on determining the molecular mechanisms that underlie polymicrobial infections of the respiratory tract, including otitis media (or middle ear infections, a highly prevalent pediatric disease worldwide), cystic fibrosis, chronic rhinosinusitis and COPD, among others. Her laboratory also studies bacterial biofilms in an effort to develop novel strategies for effective eradication of the associated highly recalcitrant diseases. Publications

                  Jurcisek JA, Hofer LK, Goodman SD, Bakaletz LO. Monoclonal antibodies that target extracellular DNABII proteins or the type IV pilus of nontypeable Haemophilus influenzae (NTHI) worked additively to disrupt 2-genera biofilms. Biofilm. 2022 Dec; 4: 100096.

                


                  Garai P, Atack JM, Wills BM, Jennings MP, Bakaletz LO, Brockman KL. Adherence of Nontypeable Haemophilus influenzae to Cells and Substrates of the Airway Is Differentially Regulated by Individual ModA Phasevarions. Microbiol Spectr. 2022 Dec 13;  e0409322.

                


                  Almeida C, Bakaletz LO. Editorial: Women in biofilms 2021. Front Cell Infect Microbiol. 2022; 12: 1035280.

                


                  Buzzo JR, Devaraj A, Gloag ES, Jurcisek JA, Robledo-Avila F, Kesler T, Wilbanks K, Mashburn-Warren L, Balu S, Wickham J, Novotny LA, Stoodley P, Bakaletz LO, Goodman SD. Z-form extracellular DNA is a structural component of the bacterial biofilm matrix. Cell. 2021 Nov 11; 184: 5740-5758.e17.

                


                  Mokrzan EM, Ahearn CP, Buzzo JR, Novotny LA, Zhang Y, Goodman SD, Bakaletz LO. Nontypeable Haemophilus influenzae newly released (NRel) from biofilms by antibody-mediated dispersal versus antibody-mediated disruption are phenotypically distinct. Biofilm. 2020 Dec; 2: 100039.

                


                  Novotny LA, Goodman SD, Bakaletz LO. Targeting a bacterial DNABII protein with a chimeric peptide immunogen or humanised monoclonal antibody to prevent or treat recalcitrant biofilm-mediated infections. EBioMedicine. 2020 Sep; 59: 102867.

                


                  Martyn L, Sethia R, Chon R, Novotny L, Goodman SD, Elmaraghy C, Bakaletz LO. Antibodies against the DNABII protein integration host factor (IHF) inhibit sinus implant biofilms. Laryngoscope. 2020 Jun; 130: 1364-1371.

                


                  Barron CL, Kamel-Abusalha LB, Sethia R, Goodman SD, Elmaraghy CA, Bakaletz LO. Identification of essential biofilm proteins in middle ear fluids of otitis media with effusion patients. Laryngoscope. 2020 Mar; 130: 806-811.

                


                  Novotny LA, Bakaletz LO. Transcutaneous immunization with a nontypeable Haemophilus influenzae dual adhesin-directed immunogen induces durable and boostable immunity. Vaccine. 2020 Feb 28; 38: 2378-2386.

                


                  Ysebaert C, Denoël P, Weynants V, Bakaletz LO, Novotny LA, Godfroid F, Hermand P. A Protein E-PilA fusion protein shows vaccine potential against nontypeable Haemophilus influenzae in mice and chinchillas. Infect Immun. 2019 May 20;  

                


                  Novotny LA, Brockman KL, Mokrzan EM, Jurcisek JA, Bakaletz LO. Biofilm biology and vaccine strategies for otitis media due to nontypeable Haemophilus influenzae. J Pediatr Infect Dis. 2019 Feb; 14: 69-77.

                


                  Atack JM, Bakaletz LO, Jennings MP. High-Depth RNA-Seq Data Sets for Studying Gene Expression Changes Mediated by Phase-Variable DNA Methyltransferases in Nontypeable Haemophilus influenzae. Microbiol Resour Announc. 2019 Jan; 8: 

                


                  Novotny LA, Goodman SD, Bakaletz LO. Redirecting the immune response towards immunoprotective domains of a DNABII protein resolves experimental otitis media. NPJ Vaccines. 2019; 4: 43.

                


                  Dagan R, Pelton S, Bakaletz L, Cohen R. First Otitis Media and Pneumococcal Conjugate Vaccine Serotypes in Infants. Pediatr Infect Dis J. 2018 Dec; 37: e351-e352.

                


                  Blakeway LV, Tan A, Lappan R, Ariff A, Pickering JL, Peacock CS, Blyth CC, Kahler CM, Chang BJ, Lehmann D, Kirkham LS, Murphy TF, Jennings MP, Bakaletz LO, Atack JM, Peak IRA, Seib KL. Moraxella catarrhalis Restriction-Modification Systems are Associated with Phylogenetic Lineage and Disease. Genome Biol Evol. 2018 Oct 18;  

                


                  Bakaletz LO, Novotny LA. Nontypeable Haemophilus influenzae (NTHi). Trends Microbiol. 2018 Aug; 26: 727-728.

                


                  Atack JM, Tan A, Bakaletz LO, Jennings MP, Seib KL. Phasevarions of Bacterial Pathogens: Methylomics Sheds New Light on Old Enemies. Trends Microbiol. 2018 Aug; 26: 715-726.

                


                  Atack JM, Murphy TF, Bakaletz LO, Seib KL, Jennings MP. Closed Complete Genome Sequences of Two Nontypeable Haemophilus influenzae Strains Containing Novel modA Alleles from the Sputum of Patients with Chronic Obstructive Pulmonary Disease. Microbiol Resour Announc. 2018 Jul; 7: 

View More Publications

Lab(s)

Center for Microbial Pathogenesis

The research program of the Bakaletz Lab is focused on determining the molecular mechanisms that underlie polymicrobial infections of the respiratory tract, including otitis media (or middle ear infections, a highly prevalent pediatric disease worldwide), cystic fibrosis, chronic rhinosinusitis and COPD, among others. Her laboratory also studies bacterial biofilms in an effort to develop novel strategies for effective eradication of the associated highly recalcitrant diseases.

Lab(s)

Center for Microbial Pathogenesis

• Center for Microbial Pathogenesis

                  Jurcisek JA, Hofer LK, Goodman SD, Bakaletz LO. Monoclonal antibodies that target extracellular DNABII proteins or the type IV pilus of nontypeable Haemophilus influenzae (NTHI) worked additively to disrupt 2-genera biofilms. Biofilm. 2022 Dec; 4: 100096.
  
  
  
                  Garai P, Atack JM, Wills BM, Jennings MP, Bakaletz LO, Brockman KL. Adherence of Nontypeable Haemophilus influenzae to Cells and Substrates of the Airway Is Differentially Regulated by Individual ModA Phasevarions. Microbiol Spectr. 2022 Dec 13;  e0409322.
  
  
  
                  Almeida C, Bakaletz LO. Editorial: Women in biofilms 2021. Front Cell Infect Microbiol. 2022; 12: 1035280.
  
  
  
                  Buzzo JR, Devaraj A, Gloag ES, Jurcisek JA, Robledo-Avila F, Kesler T, Wilbanks K, Mashburn-Warren L, Balu S, Wickham J, Novotny LA, Stoodley P, Bakaletz LO, Goodman SD. Z-form extracellular DNA is a structural component of the bacterial biofilm matrix. Cell. 2021 Nov 11; 184: 5740-5758.e17.
  
  
  
                  Mokrzan EM, Ahearn CP, Buzzo JR, Novotny LA, Zhang Y, Goodman SD, Bakaletz LO. Nontypeable Haemophilus influenzae newly released (NRel) from biofilms by antibody-mediated dispersal versus antibody-mediated disruption are phenotypically distinct. Biofilm. 2020 Dec; 2: 100039.
  
  
  
                  Novotny LA, Goodman SD, Bakaletz LO. Targeting a bacterial DNABII protein with a chimeric peptide immunogen or humanised monoclonal antibody to prevent or treat recalcitrant biofilm-mediated infections. EBioMedicine. 2020 Sep; 59: 102867.
  
  
  
                  Martyn L, Sethia R, Chon R, Novotny L, Goodman SD, Elmaraghy C, Bakaletz LO. Antibodies against the DNABII protein integration host factor (IHF) inhibit sinus implant biofilms. Laryngoscope. 2020 Jun; 130: 1364-1371.
  
  
  
                  Barron CL, Kamel-Abusalha LB, Sethia R, Goodman SD, Elmaraghy CA, Bakaletz LO. Identification of essential biofilm proteins in middle ear fluids of otitis media with effusion patients. Laryngoscope. 2020 Mar; 130: 806-811.
  
  
  
                  Novotny LA, Bakaletz LO. Transcutaneous immunization with a nontypeable Haemophilus influenzae dual adhesin-directed immunogen induces durable and boostable immunity. Vaccine. 2020 Feb 28; 38: 2378-2386.
  
  
  
                  Ysebaert C, Denoël P, Weynants V, Bakaletz LO, Novotny LA, Godfroid F, Hermand P. A Protein E-PilA fusion protein shows vaccine potential against nontypeable Haemophilus influenzae in mice and chinchillas. Infect Immun. 2019 May 20;  
  
  
  
                  Novotny LA, Brockman KL, Mokrzan EM, Jurcisek JA, Bakaletz LO. Biofilm biology and vaccine strategies for otitis media due to nontypeable Haemophilus influenzae. J Pediatr Infect Dis. 2019 Feb; 14: 69-77.
  
  
  
                  Atack JM, Bakaletz LO, Jennings MP. High-Depth RNA-Seq Data Sets for Studying Gene Expression Changes Mediated by Phase-Variable DNA Methyltransferases in Nontypeable Haemophilus influenzae. Microbiol Resour Announc. 2019 Jan; 8: 
  
  
  
                  Novotny LA, Goodman SD, Bakaletz LO. Redirecting the immune response towards immunoprotective domains of a DNABII protein resolves experimental otitis media. NPJ Vaccines. 2019; 4: 43.
  
  
  
                  Dagan R, Pelton S, Bakaletz L, Cohen R. First Otitis Media and Pneumococcal Conjugate Vaccine Serotypes in Infants. Pediatr Infect Dis J. 2018 Dec; 37: e351-e352.
  
  
  
                  Blakeway LV, Tan A, Lappan R, Ariff A, Pickering JL, Peacock CS, Blyth CC, Kahler CM, Chang BJ, Lehmann D, Kirkham LS, Murphy TF, Jennings MP, Bakaletz LO, Atack JM, Peak IRA, Seib KL. Moraxella catarrhalis Restriction-Modification Systems are Associated with Phylogenetic Lineage and Disease. Genome Biol Evol. 2018 Oct 18;  
  
  
  
                  Bakaletz LO, Novotny LA. Nontypeable Haemophilus influenzae (NTHi). Trends Microbiol. 2018 Aug; 26: 727-728.
  
  
  
                  Atack JM, Tan A, Bakaletz LO, Jennings MP, Seib KL. Phasevarions of Bacterial Pathogens: Methylomics Sheds New Light on Old Enemies. Trends Microbiol. 2018 Aug; 26: 715-726.
  
  
  
                  Atack JM, Murphy TF, Bakaletz LO, Seib KL, Jennings MP. Closed Complete Genome Sequences of Two Nontypeable Haemophilus influenzae Strains Containing Novel modA Alleles from the Sputum of Patients with Chronic Obstructive Pulmonary Disease. Microbiol Resour Announc. 2018 Jul; 7: 
  
  

View More Publications

• Jurcisek JA, Hofer LK, Goodman SD, Bakaletz LO. Monoclonal antibodies that target extracellular DNABII proteins or the type IV pilus of nontypeable Haemophilus influenzae (NTHI) worked additively to disrupt 2-genera biofilms. Biofilm. 2022 Dec; 4: 100096.
• Garai P, Atack JM, Wills BM, Jennings MP, Bakaletz LO, Brockman KL. Adherence of Nontypeable Haemophilus influenzae to Cells and Substrates of the Airway Is Differentially Regulated by Individual ModA Phasevarions. Microbiol Spectr. 2022 Dec 13; e0409322.
• Almeida C, Bakaletz LO. Editorial: Women in biofilms 2021. Front Cell Infect Microbiol. 2022; 12: 1035280.
• Buzzo JR, Devaraj A, Gloag ES, Jurcisek JA, Robledo-Avila F, Kesler T, Wilbanks K, Mashburn-Warren L, Balu S, Wickham J, Novotny LA, Stoodley P, Bakaletz LO, Goodman SD. Z-form extracellular DNA is a structural component of the bacterial biofilm matrix. Cell. 2021 Nov 11; 184: 5740-5758.e17.
• Mokrzan EM, Ahearn CP, Buzzo JR, Novotny LA, Zhang Y, Goodman SD, Bakaletz LO. Nontypeable Haemophilus influenzae newly released (NRel) from biofilms by antibody-mediated dispersal versus antibody-mediated disruption are phenotypically distinct. Biofilm. 2020 Dec; 2: 100039.
• Novotny LA, Goodman SD, Bakaletz LO. Targeting a bacterial DNABII protein with a chimeric peptide immunogen or humanised monoclonal antibody to prevent or treat recalcitrant biofilm-mediated infections. EBioMedicine. 2020 Sep; 59: 102867.
• Martyn L, Sethia R, Chon R, Novotny L, Goodman SD, Elmaraghy C, Bakaletz LO. Antibodies against the DNABII protein integration host factor (IHF) inhibit sinus implant biofilms. Laryngoscope. 2020 Jun; 130: 1364-1371.
• Barron CL, Kamel-Abusalha LB, Sethia R, Goodman SD, Elmaraghy CA, Bakaletz LO. Identification of essential biofilm proteins in middle ear fluids of otitis media with effusion patients. Laryngoscope. 2020 Mar; 130: 806-811.
• Novotny LA, Bakaletz LO. Transcutaneous immunization with a nontypeable Haemophilus influenzae dual adhesin-directed immunogen induces durable and boostable immunity. Vaccine. 2020 Feb 28; 38: 2378-2386.
• Ysebaert C, Denoël P, Weynants V, Bakaletz LO, Novotny LA, Godfroid F, Hermand P. A Protein E-PilA fusion protein shows vaccine potential against nontypeable Haemophilus influenzae in mice and chinchillas. Infect Immun. 2019 May 20;
• Novotny LA, Brockman KL, Mokrzan EM, Jurcisek JA, Bakaletz LO. Biofilm biology and vaccine strategies for otitis media due to nontypeable Haemophilus influenzae. J Pediatr Infect Dis. 2019 Feb; 14: 69-77.
• Atack JM, Bakaletz LO, Jennings MP. High-Depth RNA-Seq Data Sets for Studying Gene Expression Changes Mediated by Phase-Variable DNA Methyltransferases in Nontypeable Haemophilus influenzae. Microbiol Resour Announc. 2019 Jan; 8:
• Novotny LA, Goodman SD, Bakaletz LO. Redirecting the immune response towards immunoprotective domains of a DNABII protein resolves experimental otitis media. NPJ Vaccines. 2019; 4: 43.
• Dagan R, Pelton S, Bakaletz L, Cohen R. First Otitis Media and Pneumococcal Conjugate Vaccine Serotypes in Infants. Pediatr Infect Dis J. 2018 Dec; 37: e351-e352.
• Blakeway LV, Tan A, Lappan R, Ariff A, Pickering JL, Peacock CS, Blyth CC, Kahler CM, Chang BJ, Lehmann D, Kirkham LS, Murphy TF, Jennings MP, Bakaletz LO, Atack JM, Peak IRA, Seib KL. Moraxella catarrhalis Restriction-Modification Systems are Associated with Phylogenetic Lineage and Disease. Genome Biol Evol. 2018 Oct 18;
• Bakaletz LO, Novotny LA. Nontypeable Haemophilus influenzae (NTHi). Trends Microbiol. 2018 Aug; 26: 727-728.
• Atack JM, Tan A, Bakaletz LO, Jennings MP, Seib KL. Phasevarions of Bacterial Pathogens: Methylomics Sheds New Light on Old Enemies. Trends Microbiol. 2018 Aug; 26: 715-726.
• Atack JM, Murphy TF, Bakaletz LO, Seib KL, Jennings MP. Closed Complete Genome Sequences of Two Nontypeable Haemophilus influenzae Strains Containing Novel modA Alleles from the Sputum of Patients with Chronic Obstructive Pulmonary Disease. Microbiol Resour Announc. 2018 Jul; 7:

Professional Experience

2020 - Present Scientific Advisory Board, Clarametyx Biosciences, Scientific Founder and Member2017 - Present Scioto Biosciences, Scientific Founder2017 - Present Internal Advisory Board, Cure Cystic Fibrosis Columbus (C3), Member2012 - Present Board of Directors, International Society for Otitis Media (ISOM), Member2008 - Present The Research Institute at Nationwide Children’s Hospital, The Ohio State University, Professor, Dept. of Otolaryngology2008 - Present The Ohio State University, Professor, Dept. of Otolaryngology2007 - Present The Research Institute at Nationwide Children’s Hospital, The Ohio State University, Professor, Dept. of Pediatrics2007 - Present The Research Institute at Nationwide Children’s Hospital, Vice President for Basic Science Research2006 - Present Abigail Wexner Research Institute at Nationwide Children’s Hospital, Vice President, Basic Sciences Research2003 - Present Abigail Wexner Research Institute at Nationwide Children’s Hospital, Director, Center for Microbial Pathogenesis2000 - Present Abigail Wexner Research Institute at Nationwide Children’s Hospital, The Ohio State University, Professor, Dept. of Pediatrics2000 - Present Abigail Wexner Research Institute at Nationwide Children’s Hospital, The Ohio State University, Professor, Dept. of Pediatrics2021 - 2023 Ohio Third Frontier Commission, Member2015 - 2019 National Institutes of Health, Host Interactions with Bacterial Pathogens (HIBP) Study Section, Member2006 - 2007 Vice President for Basic Science Research, Columbus Children’s Research Institute2000 - 2007 Children’s Research Institute, The Ohio State University, Professor, Dept. of Pediatrics1998 - 2000 Children’s Research Institute, The Ohio State University, Associate Professor, Dept. of Pediatrics1998 - 2000 2000 Children’s Research Institute, The Ohio State University, Associate Professor, Dept. of Pediatrics1993 - 1998 The Ohio State University, Associate Professor, Dept. of Otolaryngology1993 - 1998 The Ohio State University, Associate Professor, Dept. of Otolaryngology1985 - 1986 The Ohio State University, Post-doctoral Researcher, Dept. of Otolaryngology1985 - 1986 The Ohio State University, Post-doctoral Researcher, Dept. of Otolaryngology

Professional Experience

2020 - Present Scientific Advisory Board, Clarametyx Biosciences, Scientific Founder and Member2017 - Present Scioto Biosciences, Scientific Founder2017 - Present Internal Advisory Board, Cure Cystic Fibrosis Columbus (C3), Member2012 - Present Board of Directors, International Society for Otitis Media (ISOM), Member2008 - Present The Research Institute at Nationwide Children’s Hospital, The Ohio State University, Professor, Dept. of Otolaryngology2008 - Present The Ohio State University, Professor, Dept. of Otolaryngology2007 - Present The Research Institute at Nationwide Children’s Hospital, The Ohio State University, Professor, Dept. of Pediatrics2007 - Present The Research Institute at Nationwide Children’s Hospital, Vice President for Basic Science Research2006 - Present Abigail Wexner Research Institute at Nationwide Children’s Hospital, Vice President, Basic Sciences Research2003 - Present Abigail Wexner Research Institute at Nationwide Children’s Hospital, Director, Center for Microbial Pathogenesis2000 - Present Abigail Wexner Research Institute at Nationwide Children’s Hospital, The Ohio State University, Professor, Dept. of Pediatrics2000 - Present Abigail Wexner Research Institute at Nationwide Children’s Hospital, The Ohio State University, Professor, Dept. of Pediatrics2021 - 2023 Ohio Third Frontier Commission, Member2015 - 2019 National Institutes of Health, Host Interactions with Bacterial Pathogens (HIBP) Study Section, Member2006 - 2007 Vice President for Basic Science Research, Columbus Children’s Research Institute2000 - 2007 Children’s Research Institute, The Ohio State University, Professor, Dept. of Pediatrics1998 - 2000 Children’s Research Institute, The Ohio State University, Associate Professor, Dept. of Pediatrics1998 - 2000 2000 Children’s Research Institute, The Ohio State University, Associate Professor, Dept. of Pediatrics1993 - 1998 The Ohio State University, Associate Professor, Dept. of Otolaryngology1993 - 1998 The Ohio State University, Associate Professor, Dept. of Otolaryngology1985 - 1986 The Ohio State University, Post-doctoral Researcher, Dept. of Otolaryngology1985 - 1986 The Ohio State University, Post-doctoral Researcher, Dept. of Otolaryngology

Professional Experience

2020 - Present Scientific Advisory Board, Clarametyx Biosciences, Scientific Founder and Member2017 - Present Scioto Biosciences, Scientific Founder2017 - Present Internal Advisory Board, Cure Cystic Fibrosis Columbus (C3), Member2012 - Present Board of Directors, International Society for Otitis Media (ISOM), Member2008 - Present The Research Institute at Nationwide Children’s Hospital, The Ohio State University, Professor, Dept. of Otolaryngology2008 - Present The Ohio State University, Professor, Dept. of Otolaryngology2007 - Present The Research Institute at Nationwide Children’s Hospital, The Ohio State University, Professor, Dept. of Pediatrics2007 - Present The Research Institute at Nationwide Children’s Hospital, Vice President for Basic Science Research2006 - Present Abigail Wexner Research Institute at Nationwide Children’s Hospital, Vice President, Basic Sciences Research2003 - Present Abigail Wexner Research Institute at Nationwide Children’s Hospital, Director, Center for Microbial Pathogenesis2000 - Present Abigail Wexner Research Institute at Nationwide Children’s Hospital, The Ohio State University, Professor, Dept. of Pediatrics2000 - Present Abigail Wexner Research Institute at Nationwide Children’s Hospital, The Ohio State University, Professor, Dept. of Pediatrics2021 - 2023 Ohio Third Frontier Commission, Member2015 - 2019 National Institutes of Health, Host Interactions with Bacterial Pathogens (HIBP) Study Section, Member2006 - 2007 Vice President for Basic Science Research, Columbus Children’s Research Institute2000 - 2007 Children’s Research Institute, The Ohio State University, Professor, Dept. of Pediatrics1998 - 2000 Children’s Research Institute, The Ohio State University, Associate Professor, Dept. of Pediatrics1998 - 2000 2000 Children’s Research Institute, The Ohio State University, Associate Professor, Dept. of Pediatrics1993 - 1998 The Ohio State University, Associate Professor, Dept. of Otolaryngology1993 - 1998 The Ohio State University, Associate Professor, Dept. of Otolaryngology1985 - 1986 The Ohio State University, Post-doctoral Researcher, Dept. of Otolaryngology1985 - 1986 The Ohio State University, Post-doctoral Researcher, Dept. of Otolaryngology

2020 - Present Scientific Advisory Board, Clarametyx Biosciences, Scientific Founder and Member2017 - Present Scioto Biosciences, Scientific Founder2017 - Present Internal Advisory Board, Cure Cystic Fibrosis Columbus (C3), Member2012 - Present Board of Directors, International Society for Otitis Media (ISOM), Member2008 - Present The Research Institute at Nationwide Children’s Hospital, The Ohio State University, Professor, Dept. of Otolaryngology2008 - Present The Ohio State University, Professor, Dept. of Otolaryngology2007 - Present The Research Institute at Nationwide Children’s Hospital, The Ohio State University, Professor, Dept. of Pediatrics2007 - Present The Research Institute at Nationwide Children’s Hospital, Vice President for Basic Science Research2006 - Present Abigail Wexner Research Institute at Nationwide Children’s Hospital, Vice President, Basic Sciences Research2003 - Present Abigail Wexner Research Institute at Nationwide Children’s Hospital, Director, Center for Microbial Pathogenesis2000 - Present Abigail Wexner Research Institute at Nationwide Children’s Hospital, The Ohio State University, Professor, Dept. of Pediatrics2000 - Present Abigail Wexner Research Institute at Nationwide Children’s Hospital, The Ohio State University, Professor, Dept. of Pediatrics2021 - 2023 Ohio Third Frontier Commission, Member2015 - 2019 National Institutes of Health, Host Interactions with Bacterial Pathogens (HIBP) Study Section, Member2006 - 2007 Vice President for Basic Science Research, Columbus Children’s Research Institute2000 - 2007 Children’s Research Institute, The Ohio State University, Professor, Dept. of Pediatrics1998 - 2000 Children’s Research Institute, The Ohio State University, Associate Professor, Dept. of Pediatrics1998 - 2000 2000 Children’s Research Institute, The Ohio State University, Associate Professor, Dept. of Pediatrics1993 - 1998 The Ohio State University, Associate Professor, Dept. of Otolaryngology1993 - 1998 The Ohio State University, Associate Professor, Dept. of Otolaryngology1985 - 1986 The Ohio State University, Post-doctoral Researcher, Dept. of Otolaryngology1985 - 1986 The Ohio State University, Post-doctoral Researcher, Dept. of Otolaryngology

2020 - Present Scientific Advisory Board, Clarametyx Biosciences, Scientific Founder and Member

Contact Information

Center for Microbial Pathogenesis

Call us at: (614)722-2915

Fax us at: (614)722-2818

Email Lauren O Bakaletz

                    Abigail Wexner Research Institute700 Childrens DriveColumbus, OH 43205 (map)

Contact Information

Center for Microbial Pathogenesis

Call us at: (614)722-2915

Fax us at: (614)722-2818

Email Lauren O Bakaletz

                    Abigail Wexner Research Institute700 Childrens DriveColumbus, OH 43205 (map)

Contact Information

Center for Microbial Pathogenesis

Call us at: (614)722-2915

Fax us at: (614)722-2818

Email Lauren O Bakaletz

                    Abigail Wexner Research Institute700 Childrens DriveColumbus, OH 43205 (map)

Center for Microbial Pathogenesis

Call us at: (614)722-2915

Fax us at: (614)722-2818

Email Lauren O Bakaletz

                    Abigail Wexner Research Institute700 Childrens DriveColumbus, OH 43205 (map)

Call us at: (614)722-2915

Fax us at: (614)722-2818

Email Lauren O Bakaletz

                    Abigail Wexner Research Institute700 Childrens DriveColumbus, OH 43205 (map)

Call us at: (614)722-2915

Fax us at: (614)722-2818

Email Lauren O Bakaletz

                    Abigail Wexner Research Institute700 Childrens DriveColumbus, OH 43205 (map)

• Call us at:
• (614)722-2915
• Fax us at:
• (614)722-2818
• Email Lauren O Bakaletz
• Abigail Wexner Research Institute700 Childrens DriveColumbus, OH 43205 (map)